Note: Descriptions are shown in the official language in which they were submitted.
1~8S31 "
The invention relates to new optionally racemic or optically
active pyrimido(l,2a) heterocyclic compounds of the general formula
R
(~ =R2
R O
wherein R represents an alkyl group of 1 to 4 carbon atoms;
R represents an alkyl group of 1 to 4 carbon atoms; -
R2 represents hydrogen, an alkyl group of 1 to 6 carbon atoms
an alkyl group of 1 to 6 carbon atoms substituted by one or
two phenyl groups or by a tert.butoxy carbonyl group; acetyl;
or phenyl;
R3 represents hydrogen; or -~
R2 and R3 together with the adjacent nitrogen atom represent a
piperidyl group
.
, ~ .
. ~ .
~ ` ~
lV~31
T;lis invention further provides novel processes for the prepara-
tion of the new pyrimido(l,2a)heterocyclic compounds of the general
formula I.
~ a) reacting a racemic or optically active pyrimido(l,2a)
quarternary compound of formula II
CON= 3 11
R O
wherein the groups R, Rl, R2, R3 are as defined above and X represents `:
an anion, with an organic or inorganic base, or with a salt of such base; -
(b) reacting a racemic or optically active compound of the .
formula II, as defined in (a) above, in a protic solvent with an organic `:
or inorganic base, or with a salt of such base, to provide a compound of -~
formula III
R -
y I .:
R2
: ~ N ~ ````~R3 III -:
Il 11 ` `
:
wherein R, Rl, R2 and R3 are as defined above and Y represents a hydroxy,
la~
alkoxy, nitrile, or amino group, and converting the thus obtained compound
to a compound of formula I by eliminating therefrom HY; or -
(c) reacting a racemic or optically active compound of formula
IV
R
IV
N ~ C2H
I
R 0
with an amine of formula V: R2 ,
HN
R3 ::
wherein R, Rl, R2 and R3 are as defined above.
The method a) is preferably carried ~ut at 0 to 200C.
As aprotic solvents aromatic hydrocarbons, preferably benzene, -
halogenated hydrocarbons, preferably chlorobenzene, chloroform, carbon~
tetrachloride, aliphatic ketones, preferably
~;
"~' ~
''
la~3l
acetone, methyl ethyl ketone, ethers, preferably diethylether, dioxane,
esters, preferably ethylformite, ethylacetate or a mixture of the above
solvents may be employed.
As an organic base trialkylamines, preferably triethylamine, tri-
methylamine, tributylamine and nitrogen containing aroDatic heterocyclic
compounds, such as pyridine may be used. If desired, an excess of the organ~c
base may serve as an aprotic solvent.
As a salt of an inorganic base alkali metal hydrogen carbonates,
preferably sodium or potassium hytrogen carbonate, alkali metal carbonates,
preferably sodium or potassium carbonate, a salt of an alkali metal with an
organic acid such as sodium or potassium acetate or alkali earth metal car- ~-
bonates, preferably calcium carbonate may be used. -
The method b) is preferably performed ~t temperatures of 0 to 200C.
As protic solvents water, alcohols such as ethanol, n-propanol,
isopropanol, n-butanol, glycol or a mixture of said solvents can be employed.
As a solvent the mixtures of the solvents enumerated for both
methods a) and b) may also be used.
As organic bases trialkyl-, dialkyl-, alkylamines, preferably tri-
ethylamine, diethylamine, n-butylamine, tetraalkylammoniumhydroxide, prefer-
2~ ably tetraethylammoniumhydroxide and nitrogen containing heterocyclic com-
pounds, such as pyridine or piperidine may be employed.
As inorganic bases alkali metal hydroxides, preferably sodium
hydroxide, potassium hydroxide, alkali metal carbonates, preferably sodium
carbonate, potassium carbonate, alkali metal hydrogen carbonates preferably
sotium hydrogen carbonate, potassium hytrogen carbonate, alkali -~arth metal
hydroxides, such as calcium hydroxide, alkali earth metal carbonates, such
as calcium carbonate, alkali metal cyanides, ammonium hydroxide, ammonium ;
carbonate, ammonium hydrogen carbonate or gaseous ammonia may be used.
Working according to methods a) and b), either the compound of the
~eneral formula I is precipitated from the reaction mixture and thus it can
1088S31
be removed by filtration, or after evaporation the residue is recrystallizet
from a suitable solvent and thus the compound of the general fo D la I is
obtained.
According to one of the embodiments of method c) a compound of the
general formula IV is reacted with an amine of the general fo D la V by dis~
solving the compound of the general formuls IV in an organic solvent, profor-
ably in chlorinated hydrocarbons, particularly in chloroform or in ethers,
such as dioxane, tetrahydrofurane and a trialkyl amine, preferably triethyl-
amine or tribut~lamine is added, whereafter an acid halide, preferably tri-
methyl acetic acid halide, such as trimethyl acetic acid chloride or chloro-
formic acid ester, preferably chloroformic acit methyl, ethyl or isopropyl-
ester is added dropwise to the obtained solution at -30C to 50C, preferably
at -20C to 0C. The amine of the general fo D la V is then added dropwise, `
if desired, dissolved in the solvent given above or when using the acit ad-
dition salt thereof it is added together with trialkylamine, such as triethyl-
amine or tributylamine, the reaction mixture is then stirred at a temperature
range given above, the mixture is shaken out with an aqueous solution of
sodium hydrogen carbonate and then with water whereafter it is allowed to
~arm to room temperature.
The reaction mixture is evaporated after drying and the residue is
recrystallized from a suitable solvent.
According to another feature of method c) a compound of the general
fo D la IV is reacted with an amine of the general formula V preferably in an
organic solvent in the presence of a water-binding agent. Preferred water
hinding agents are, for example, carbodiimides such as dicyclo-hexyl-
carbodiimide. In such cases the reaction is preferably carriod out in the
presence of l-hydroxy-benzotriazole, N-hydroxy-succinic imide or pentachloro-
phenol, as by the presence of those substances side reactions are minimizod.
As solvents aromatic hydrocarbons, such as benzene, chlorinated
3Q hydrocarbons, such as chloroform, chlorobenzene, ketones, such as acetono,
1088S31
methylethylketone, ethers, such as dioxane, tetrahydrofurane, esteTs such as
ethyl acetate are preferred or when using carbodiimide soluble in aqueous
alcohol, a mixture of water and alcohol or a mixture of the said solvents can
be employed.
The reaction is carried out at temperatures of 20 to 100C. After
the reaction is completed, the precipitated urea is removed by filtration and
the residue obtained sfter the evaporation of the filtrate is recrystallizod
from a suitable solvent and thus the pyrimido~l,2a)heterocycle of the genoral
formula I is obtained.
The pyrimido~l,2a)heterocyclic ~ompounds of the general formulae II
and IV can be preparet according to Hungarian Patent Specifications Nos:
156.119, 158.085, 162.384, 162.373, 166.577 ant Dutch Patent Specification
No: 7.212,286, whereas the amines of the general formula V are available.
The invention also includes the racemic and optically active forms
of the pyrimido~l,2a)heterocyclic compounds of the general formula I, this is
only possible, if at least one of R and R is different from hytrogen and R1
and R together do not form a -tCH-CH)2 chain. The optically active compounds
of the general formula I may be obtained by resolving the racemic compounds of
the general formula I by methods known in the art, or optically active start-
ing materials of the general formula II respectively IV are uset. .
The term "optionally substituted amino" means as acylamino, prefer-
ably acetylamino, alkylamino, such as methylamino, ethylamino, dialkylamino,
preferably dimethylamino or diethylamino group, the term "optionally substi-
tuted hydroxy" indicates an alkoxy group, such as methoxy, ethoxy, aralkoxy
such as benzyloxy group, the term "optionally substitutet alkyl group" means
a straight or branched chain alkyl of one to 6 carbon atoms, optionally bear-
ing an optionallr substitutet amino, optionally substituted hydroxy, keto,
optionally substituted aryl, carboxy or a group derivet from a carboxylic
acid, the term "substituted aryl group" as used herein means phenyl or
3~ naphthyl groups, optionally substituted by optionally substituted amino, alkyl
lO~S3~ ~
of one to 6 carbon atoms, optionally substituted hydroxy, carboxy or a group
derived from carboxylic acid or nitro groups, the term "optionally substituted
aralkyl group" as used herein means preferably alkyl of one to 6 carbon atoms,
optionally substituted hydroxy, optionally substituted amino, nitro, carboxy
groups or a group derived from a carboxylic acid and the term "optionally sub-
stitutet heterocyclic group" means five-, six- or seven-membered partially or
completely saturated mono- resp. bicyclic heterocycles, containing nitrogen,
oxygen, sulphur atoms or nitrogen and oxygen, optionally substituted by
alkyl, acyl or alkoxy of one to 6 carbon atoms and the term ~optionally sub-
stituted cycloalkyl group" means a five-, six- or seven-membered cycloalkyl
group, optionally substituted by an alkyl group of one to 6 carbon atoms.
The compounds of the general formula I possess a significant degree
of pharmacological activity, some representatives of the compounds of the
formula I are particularly effective as antiphlogistics, PG antagonists,
inhibit the blood platelet aggregation and exhibit analgetic activity. Some
derivatives show some other favourable effects on the central nervous system.
The pharmacologlcal and toxicological tests resulted under various
conditions a significant degree of activity and low toxicity.
The test results are demonstrated in connection with 3-carbamoyl-1,
2C 6-dimethyl-4-oxo-1,6,7,8-tetrahydTo-4H-pyrido~1,2a)pyrimidine tfurther on
CH-105~. In our investigations antiphlogistics known from the art such as
Phenylbutazone, *Aspirin, Indomethacinum, *Mebron and Amidazophenum were used
for comparison.
The antiphlogistic activity of CH-105 was tested by a method known
in the art that is the rat paw oedema method (Domenju, R.: Ann. Univ.
Saraviensis 1, 317, 1953).
The test results obtained by various methods and the outstanding
activity of CH-105 are shown in Table.l.
Trade Mark
10~S31
Table 1
Substance Dose Oetema inhibiting effect in t ;
mg/kg 1 hour 2 hours 24 hours
after the administration of the
substance
.
CH-105 100 25 34
300 45 52 8
~Mebron 100 8 22
300 25 25 3
Phenylburazone 100 2 2
200 11 10 3
According to the latest data in the literature the prostaglandins
pla~ an important role in the formation of inflammations CVane, J.R.:
Prostaglandins in inflammatory response, In.: Inflammation, 1972. N.Y.
Academic Press). Thus it seemet bo be appropriate to test the effectivity
of the substance of the invention in the inflammation response caused by
prostaglandine El and E2 particularly from the point of view of the vessel
wall permeability, which plays an important role in the inflammation.
Table 2
, .
Substance Dose Oedema inhibition % Vessel wall permeability
mg/~g inhibition %
PGEl PGE2 PGEl PGB `
CH-105 200 30 31 40 35
: 500 42 45 40 50
*Aspirin 200 41 20 30 25 :
500 45 54 42 50
Phen~lbutazone 100 5 10 10 5
200 15 28 20 20
'~
~ 10 The tata of the table 2 show, that CH-105 exhibits an activity of
t'~ ' the same range like the known active prostaglandine antagonist aspirine of
the CH-105 as an oedema inhibitoT or a vessel wall permeability reducing
agent CVane, J.R. Hospital Practice, 7, ~1 /1972/). Favourable properties
were found in tests carried out by the method of Northover ~J. Path, Bect.
35, 365, 1963).
.
Trade Mark
_ g _
S3~
Table 3
Substance DoseAntiphlogistic activity (~)
mg/kg 1 hour 2 hours 24 hours
_
CH-105 100 40 55 30
~Mebron 100 23 23 0
Phenylbutazone 100 18 20 0
The significant antiphlogistic activity of CH-105 is atvantageouslr
accompanied by analgetic activity. The motified writhing test tWitkin et al.:
J. Pharm. exp. Ther. 113, 400 /1961/) gave the following results:
Table 4
Substance ED50 Therapeutical index
mg/kg
CH-105 70 14
*Mebron 380 4.3
Phen~lbutazone 63 5.5
Indomethacinum 2.4 12
.
The obtainet results show the fa~ourable toxicity of CH-105.
Table 5
. .
Substance LD50 mg/kg per os
rats mice
CH-105 750 975
*Aspirine 1600 1100
Phenylbutazone 770 350
In the course of chronical tests CH-105 did not prove to be ulcer-
ogenic, the substance was administered to one month old rats in a dose of
50 mg/kg. On the base of our investigations is CH-105 a significant anti-
phlogistic possessing also antianalgetic activity ant a favourable thera-
peutic index.
*
Trade Mark
_ 10 -
8S31
The compounds of the general formula I can be used as active in-
gredients in pharmaceutical compositions, admixed with inert. non-toxic solid
or semi-solid diluents or carriers.
Preferred pharmaceutical forms of the present invention are solid
forms, such as tablets, capsules, dragées or liquid forms, such as solutions,
suspensions or emulsions.
As carriers the generally used substances, such as talcum, calcium
carbonate, magnesium stearate, water, polyethylene glycolate may be employed.
The compositions contain, if desired some other conYentionally used
excipients, such as emulsifiers, substances promoting decomposition. The
further details of our invention can be found in the following non-limiting
Examples.
Example 1
15 g. of 1,6-dimethyl-3-carbamoyl-4-oxo-6,7,8,9-tetrahydro-4H-
pyrido-tl,2a)pyrimidinium methylsulfate are heated in the mixture of 450 ml.
of benzene and 50 g. of triethylamine and after cooling the mixture is -
allowed to stand overnight in a refrigerator. The precipitated crystals are
filtered. The filtrate is evaporated. The obtained residue is recrystallized ~`
from ethanol and thus yellow 1,6-dimethyl-3-carbamoyl-4-oxo-1,6,7,8-tetra-
hy~ro-4H-pyrido(1,2a)pyrimidine is obtained. Melting point: 171 - 172C
! AnalysiS:
calculated: C 59.71 % H 6.83 % N 18.99 %
found: C 59.85 % H 6.87 % N 19.03 %.
Example 2 -
50 g. of 1,6-dimethyl-3-carbamoyl-4-oxo-6,7,8,9-tetrahydro-4H-
pyrido~l,2-a)pyridinium methylsulfate are dissolYed in 150 ml. of water a~d
I the pH of the solution is adjusted to neutral by adding 13.9 g. of solid
i sodium hydrogen carbonate and from the resulting 1,6-dimethyl-3-carbamoyl-
9a-hydroxy-4-oxo-1,6 J 7,8,9,9a-hexahydro-4H-pyrido(1,2a)pyrimidine 1,6-di-
3Q methyl-3-carbamoyl-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2a)pyrimidine is
la~ssi3l
formed by discharging water and the product is precipitated from the solution
in the form of crystals.
After standing for 2 hours at room temperature the crystals are
filtered, washed with water and dried. 26.5 of yellow crystals are obtained,
melting point: 165 - 171C. The aqueous filtrate is shaken out with chloro-
form and the chloroform solution is evaporated and a further 1.8 g. of yellow
crystals are obtained, melting point: 162 - 168C.
Total yield: 86%. The combined crystalline substance is re-
crystallized from ethanol and thus the melting point of the resulting 1,6-
dimethyl-3-carbamoyl-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2a)pyrimidine is
raised to 170 - 172C. There is no decrease in the melting point compared
with the product of Example I.
Example 3
15.3 g. of 1,6-dimethyl-3-~N-acetyl-carbamoyl)-4-oxo-6,7,8,9-
te~rahydro-4H-pyrido(1,2a)pyridinium methyl sulfate are dissolved in 50 ml.
of water. The solution is neutralized with a 5% sodium carbonate solution
and thus 1,6-dimethyl-3-(N-acetyl-carbamoyl)-9a-hydroxy-4-oxo-1,6,7,8,9,9a-
hexahydro-4H-pyridotl,2a)pyrimidine is formet which is converted to 1,6-
dimethyl-3-(N-acetyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2a)
2Q pyrididine by discharge of water and it is precipitated from the aqueous
solution. The precipitated yellow crystals are filtered, covered with water,
and dried. 9.2 g. (86%) of the product is obtained, melting point: 182 -
184C. After recrystallization from ethanol the melting point of the re-
sulting 1,6-dimethyl-3-(N-acetyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-
pyrido(l,2a)pyrimidine is 183 - 185C.
Analysis:
calculated: C 59.30 % H 6.51 % N 15.96 %
found: C 59.80 % H 6.64 $ N 15.68 %.
Example 4
6.38 g. of 1-methyl-3-carbamoyl-4-oxo-6,7,8,9-tetrahydro-4H-
1088S31
pyrido(l,2a)pyrimidinium methyl sulfate are dissolved in 50 ml. of water.
The solution is neutralized with solid potassium carbonate and thus l-methyl-
3-carbamoyl-9a-hydroxy-4-oxo-1,6,7,8,9,9a-hexahydro-4H-pyrido(1,2a)-pyrimidine
is obtained which is transferred under discharge of water to l-methyl-3-car-
bamoyl-4-oxo-1,6,7,8-tetrahydro-4H-pyridotl,2a)pyrimidine which is precipitat-
ed in crystalline form. The yellow crystals are filtered, covered with water
and dried. 3.9 g t94 %) of yellow substance is obtained. After recrystal-
lization the melting point of the obtained l-methyl-3-carbamoyl-4-oxo-1,6,7,
8-tetrahydro-4H-pyrido(1,2a)pyrimidine is 241 - 242C. `
Analysis:
calculated: C 57.96 ~ H 6.32 % N 20.28 %
found: C 58.09 ~ H 6.27 % N 20.25 %.
Example 5 -
0.89 g. (4 mmoles) of 1,6-dimethyl^3-carboxy-4-oxo-1,6,7,8-
tetrahydro-4H-pyrido(1,2a)pyrimidine are dissolved in 10 ml. of chloroform
and 0.62 ml. (4.4 mmoles) of chloroformic acid ethyl ester is added drop-
wise to the mixture under stirring. After stirring for ten minutes a solu-
tion of 0.70 g. (4.2 mmoles) of glycine tertiary butyl ester hydrochloride
and 0.58 ml. (4.2 mmole) of triethylamine in 10 ml. of chloroform are added
2Q ma~ntaining the temperature during the addition and for an hour after the ` -
addition at -5 to -10C. The reaction mixture is allowed to stand over-
night in the refrigerator, washed three times with 5~ sodium hydrogen car-
bonate and three timos with water, dried over sodium sulfate ant dried. ` ;
The residual dark yellow resinous product is dissolved in the mixture of
5 ml. of ethyl acetate: pyridine: glacial acetic acid: water = 240:20: ~
6:11 and the solution is subjected to chromatography on a *Kieselgel 60 ~ --
column of size 50 cm, diameter: 1.8 cm. and of a particle size 0.063 -
0.125. Eluent solvent: ethyl acetate: pyridine: glacial acetic
acid : water = 240:20:6:11, flow rate: 30 ml. per hour. The solvent,
3Q ~hich is passed through the column is evaporated in vacuo and after evapora-
Trade Mark
- 13 -
1~8S31
tion in vacuo the residue is held for a while in vacuo of 10 2 Hgmm, to re-
move the pyridine acetate of the solvent. 1.00 g. of coloured amorphous
resinous substance is obtained, which is dissolved in 10 ml. of ethyl acetate
and while still warm, 15 ml. of cyclohexane is added. The precipitated crys-
tals are filtered and air-dried, the following day. 1~8 g. t60 %) of 1,6-
dimethyl-3-[~N-tert.butoxycarbonyl-methyl)-carbamoyl]-4-oxo-1,6,7,8-tetra-
hydro-4H-pyrido(1,2a)pyrimidine of a melting point 180 - 182C is obtained.
Analysis:
calculated: C 60.88 % H 7.51 % N 12.53 %
found: C 61.12 % H 7.70 % N 11.94 %.
Example 6
4.4 g. (0.02 moles) of 1.6 dimethyl-3-carboxy-4-oxo-1,6,7,8-tetra-
; hydro-4H 7yrido~1,2)pyrimidine and 3.1 ml. tO.022 mole) of triethylamine are
dissolved in 50 ml of chloroform and the resulting solution is cooled to
-10C. 2.1 ml. (0.022 mole) of chloroformic acid ethyl ester is added drop-
wise to the solution. After stirring for a further ten minutes a solution
of 1.95 g. (0.022 mole) of aniline in 25 ml. of chloroform is added to the
mixtùre~ and the temperature is maintained during the addition and after the
addition for an hour at -5C to -10C. The reaction mixture is allowed to
2~ stand overnight in a refrigerator and the mixture is then shaken out 3 fold
with a 5% solution of sodium hydrogen carbonate and then 3 times with water.
; The chloroform solution is dried over sodium sulfate and evaporated in vacuo.
5.7 g. (96 %) of yellow crystals of a melting point of 180C is obtained.
After recrystallization twice from ethanol 1,6-dimethyl-3-(N-phenyl-carbamoyl)-
4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2a)pyrimidine is obtained, melting
point: 189 - 190C.
Analysis:
calculated: C 68.67 % H 6.44 % N 14.13 %
found: C 68.60 ~ H 6.50 % N 14.21 %.
- 14 -
8S31
Example 7
4.4 g. (0.02 moles) of 1,6-dimethyl-3-carboxy-4-oxo-1,6,7,8-tetra-
hydro-4H-pyrido(1,2a)pyrimidine and 3.1 ml. (0.022 le) of triethylamino are
dissolved in S0 ml. of chloroform. The solution is cooled to -10C and 2.1
ml. (0.022 mole) of chloroformic acid ethyl ester is added to the solution,
whereafter 1.5 g. (0.022 mole) of methylamine hytrochloride su~pended in
25.0 ml. of chloroform and 3.1 ml. of triethylamine are also atded. The solu-
tion is stirred for 1 hour at a temperature of -5C to -10C ant the mixture
is then allowed to stand overnight in a refrigerator. The reaction mixture
is then shaken out the following day 3 times with 50 ml. of a 5% aqueous solu-
tion of sodium carbonate and then with 50 ml. of water. The chloroform solu-
tion is dried over sodium sulfate and evaporated. 3.9 g. (83 %) of yellow
product is obtained. After recrystallization from ethanol 1,6-dimethyl-3-
(N-methyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrito(1,2a)pyrimidine is
obtained, melting point: 172 - 174C.
Analysis:
calculated: C 61.26 % H 7.28 % N 17.85 %
found: C 61.08 % H 7.40 % N 17.75 %. -
Example 8
4.4 g. (0.02 mole) of 1,6-dimethyl-3-carboxy-4-oxo-1,6,7,8-tetra-
hytro-4H-pyrido(1,2a)pyrimidine and 3.1 ml. of triethylamine are dissolved
in 50 ml. of chloroform and 2.1 ml. (0.022 mole) of chloroformic acid ethyl
ester and 1.9 g. (0.022 mole) of piperidine dissolved in 25 ml. of chloro-
form are added dropwise at -10C to the solution. The reaction mixture is
stirred for a further hour at -5C to -10C ant it is allowed to stand over-
night in a refrigerator.
The following day the chloroform solution is three times shaken out
with 50 ml. of a 5% solution of sodium hydrogen carbonate and dried over sodi-
um sulfate, and evaporated. 5.2 g. ~90 %) of 1,6-dimethyl-4-oxo-(1-piperityl-
3~ car~on~l)-1,6,7,8-tetrahydro-4H-pyrido~1,2a) pyrimidine is obtained in the
- 15 -
S3i
form of yellow incrystallizable oil
Analysis:
calculated: C 66.41 % H 8.01 ~ N 14.52 ~
found: C 66.58 % H 8.20 % N 14.47 %.
Example 9
4.44 g. tO.02 mole) of 1.6-dimethyl-3-carboxy-4-oxo-1,6,7,8-tetra-
hydro-4H-pyrido~1,2a)pyrimidine and 3.1 ml. of triethylamine are dissolved
in S0 ml. of chloroform and 2.1 ml. (0.022 mole) of chloroformic acid ethyl
ester and 5.26 g. (0.022 mole) of diphenylpropylamine dissolved in 25 ml.
of chloroform are added dropwise at -10C to the solution. The reaction mix-
ture is then stirred for 1 hour at a temperature of -5C to -10C and the
mixture is then allowed to stand overnight in a refrigerator. The following
day the chloroform solution is shaken out with a 5% sodium hydrogen carbonate
solution and with water, dried over sodium sulfate and evaporated. 6.8 g.
~82 %) of yellow crystals are obtained. After recrystallization from ethanol
1,6-dimethyl-3-[N-(3,3-diphenyl-propyl)-carbamoyl]-4-oxo-1,6-7,8-tetrahydro-
4H-pyrido~1,2a)pyrimidine of a melting point of 173 - 175C is obtained.
Analysis:
calculated: C 75.15 % H 7.04 % N 10.11 %
fount: C 74.92 % H 6.96 % N 9.84 %.
Example 10
4.44 g. of 1,6-dimethyl-3-carboxy-4-oxo-1,6,7,8-tetrahydro-4H-
pyrido~l,2a~pyrimidine and 3.1 ml. of triethylamine are dissolved in chloro-
form at -10C and 2.1 ml. of chloroformic acid eth~l ester and 1.6 g. of tert~
butylamine in chloroform are added to the solution. The reaction mixture is
stirred at a temperature of -5C to -lQC and it ~9 allowed to stand overnight
in a refrigerator. The following day the chloroform solution is shaken out
~ith a 5% sodium hydrogen carbonate solution and then with water, dried over
sodium sulfate, filtered and evaporated. 5.3 g. ~95 %) of yellow crystals
are obtained. After recrystallization from ethanol 1,6-dimethyl-3-tN-tert-
- 16 -
10~8S3~
butyl-car~amo~ 4-oxo-l,6,7,8-tetrahydro-4H-pyrido(l~2a)pyTimidine is ob-
tained, melting point: 179 - 181C.
Analysis:
calculatet: C 64.96 % H 8.36 ~ N 15.15 %
found: C 64.68 % H 8.32 % N 15. 42 %.
Example 11
4.44 g. of 1,6-dimethyl-3-carboxy-4-oxo-1,6,7,8-tetrahydro-4H-
pyrido~l,2a)pyrimidine and 3~1 ml. of triethylamine are dissolved in chloro- - -
form and 2.1 ml. of chloroformic acid ethyl ester and 2.7 g. of beta-phenyl- -~
ethylamine are added to the solution at -10C. The reaction mixture is stir-
~et for 1 hour at a temperature of -5C to -10C and then allowet to stand
overnight in a refrigerator. The following day the chloroform solution is
shaken out with a 5% solution of sodium hydrogen carbonate and then with ~-
wster, dried over sodium sulfate, filtered and evaporatet. 2.1 g. of yellow
crystals are obtained. After recrystallization from ethanol 1,6-dimethyl-3- `
[N-(2-phenyl-ethyl)-carbamoyl]-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2a)
pyrimidine is obtained, melting point: 141 - 143C.
Analysis:
calculated: C 70.13 % H 7.12 % N 12.91 %
2~ found: C 69.83 % H 6.96 % N 12.74 %.
Example 12 `~
According to the method described in Example 2 but using ~-)-1,6-
dimeth~l-3-carbamoyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido(1,2a)pyrimidinium-
methylsulfatel(~-)D = -59, (c = 2, methanol)] as starting material ~)-1,6-
dimethyl-3-carbamoyl-4-oxo-1,6,7,8-tetrahydro-4H-pyrido~1,2a)pyrimitine is
obtained, melting point: 171 - 173C. ~(~)D20 = ~71 (c~2, methanol)3.
Analysis:
calculsted: C 59.71 ~ H 6.83 ~ N 18.99
ound: C 59.69 ~ H 6.78 % N 19.04 %.
- 17 _
10~8S31
Example 13
Accordlng to the method described in Example 2 but using (~)-1,6-
dimethyl-3-carbamoyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido(1,2a)pyrimidine
methosulfate [(a)D = +58.5 (c = 2, methanol)] as star~ing material (-)-1,6-
dimethyl-3-carba~oyl-4-oxo-1,6,718-tetrahydro-4H-pyrido(l,2s)pyrimidine is
obtained. [(a)D = -70, mothanol)].
Analysis:
calculated: C 59.71 % H 6.83 % N 18.99 %
found: C 59.85 % H 6.90 % N 18.92 %.
Example 14
0,lg capsule
Composition for 5000 capsules:
a./ 3-carbamoyl-1,6-dimethyl-4-oxo-1,6,7,8-tetrahydro-4H-pyrido/
1,2a/-pyTimidine /CH-105/ 500 g
b./ Potato starch 115 g
c./ Gelatine 5 g
d./ Distillet water 30 g
e./ 2 N hydrochloric acid 5 g
f./ Ethylalcohol /90~/ 60 g
g.~ Potato starch 25 g "
h.~ Talc 25 g
i.~ Stearinic acid 5 g
Method
The powder mixture of components a.t and b./ is moistened with
t~e solution of components c.~-f./ in a suitable kneading-mixing machine,
thereafter it is granulated through a 0,3 mm mesh screen and dried at 40C.
T~e granules thus obtained are regranulated through a 0,15 mm mesh screen~
~t is admixed with the homogeneous powder mixture of components g./-i.J and
filled into hard gelatine capsules in a suitable filling machine. Weight of
a capsule: 0,133 g. The finished capsules are packet in a con~entional man~
ner.
- 18 -
lO~S3~
Example 15
0,1 g tablet, coated pill, drag~e.
Composition for 5000 tablets
See Example 14.
Method
The granules prepared according to Example 14 are pressed into
tablets in a suitable tabletting machine, weight of a tablet: 0,133 g. The
- finishet tablets are per se furnished with a film coating, or they are formet
into dragée with a sugar layer.
Example 16
0,4 g tablets of coated pills of prolonged effect.
ComPosition for 1000 tablets.
c CH-105 active ingredient 400 g
Crystalline cellulose 160 g
! Eudragit lacque 7 g
Potato starch 35 g `
Talc 22 g
~ Magnesium stearate 6 g
; Method
2Q The mixture of the active ingredient and the crystalline cellulose
is granulated by the propanol solution of the Eudragit lacque in a conven-
tional manner. The homogeneous powder mixture of potato starch, talc ant
t, magnesium stearate is admixed with the dried and regranulated product ant is
formet into tablets weighing 0,63 g unter high pressure. The tablets thus
obtainet may be furnished with film- or sugar layer in a manner ~nown per se.
Example 17
,t
5Q mg injection
Comnosition for 10.000 ampoules
s,
CH-105 500 g
Sodium chloride 17 g
Sodium pyrosulphite 3 g
;~
- 19 -
-
lO~S31
Filled up to 10.000 cm3 with distilled water
Method
In a container suitable for injection purposes the solution corres-
ponding to the above composition is prepared in a manner known per se. The
nearly isotonic and isohydric solution is filled into ampoules of 1,1 cm3
under nitrogen. The sterilization is performed for 30 minutes at 120C.
Example 18
0,15 g suppository
Composition for 1000 suppositories
CH-105 150 g
Suppository mass 2.350 g
Method `-
The melt suppository mass is dried over about 60 g of anhydrous
sodium sulphate. The active ingredient is homogenized with the filtered sup-
pository mass until warm. The suppositories are formed in a suitable machine,
a~d are packed in a conventional manner. As suppository mass cocoa-butter
or synthetic base substances may be used.
Example 19
; 2 % ointment
Composition for 1000 g of ointment
CH-105 20 g
Methyl cellulose 50 g
Glycerol 100 g
Methyl-p-hydroxy-benzoate 0,5 g
Propyl-p-hydroxy-benzoate 0,3 g
Essence of perfume quantum satis
Distilled water for supplementing the
mixture to 1000 g.
Method
The methyl- and propyl-p-hydroxy-benzoates are dissolved in glycerol~
Homogenized with swelled methyl cellulose the active ingredient and the es-
sence of perfume are tissolved. The finished product is filled up with water
- 20 -
10~8S31
to 1000 g, and filled into hermethic tanks or tubes in a conventional manner.
Example 20 ~~
Composition for 1000 combination suPpositories
.
CH-lOS 75 g
Diethyl barbituric acid 15 g `
Routine 20 g
Nicotinic amide 2S g
*Witepsol-H msss 1.865 g
Method
.
The acti~e ingredient is homogenized with diethyl barbituric acid
in a kneading-mixing machine. The routine and the nicotinic amide are homo-
genized with the mass, thereafter it is homogenized with small portions of
~he suppository mass, dried over anhydrous sodium sulphate in the melt. The
suppositories weighing 2 B are formed in a suitable machine.
Example 21
Tablet, coated pill, dragées -.
Composition for 1000 tablets, coated pills, drag~es
CH-105 50 g
Ihdomethacine 10 g
Crystalline cellulose 35 g
Polivinylpyrrolidone 5 g
Colloidal silicic acid 3 g
Talc 2 g
Magnesium stearate 2 g
Method
The active ingredient and indomethacine are mixed with crystallino
cellulose ant polivinylpyrrolidone and passed through a 0,lS mm mesh screen. `~
~`~ After mixing with a fine powder mixture of colloidal silicic acid, talc and
magnesium stearate the product is directly pressed into tablets weighing
0,107 g.
Trade Mar~
- 21 -
10~S31
Remarks
According to the above examples, other active substances e.g.
alcaloit-type analgetics, dionine, codein may be finished into tablets in a
similar way in combination with CH-105.
,~ .
